Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | CTSG | P08311 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | SLC37A4 | O43826 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2496088 | 0.77 | PTGS2 (0.38) | LMNAALDH1A1MAPT | |
| SCHEMBL2469032 | 0.77 | PTGS2 (0.38) | LMNAALDH1A1MAPT | |
| SCHEMBL13299960 | 0.77 | PTGS2 (0.38) | LMNAALDH1A1MAPT | |
| SCHEMBL21166592 | 0.76 | LMNA (0.34) | LMNAMAPK1MEN1KMT2A | |
| SCHEMBL20464571 | 0.76 | LMNA (0.34) | LMNAMAPK1 | |
| SCHEMBL19219814 | 0.75 | LMNA (0.33) | LMNAMAPK1MEN1ALDH1A1MAPT | |
| SCHEMBL12265773 | 0.74 | PTGS2 (0.36) | ALDH1A1MAPT | |
| SCHEMBL2367919 | 0.74 | PTGS2 (0.36) | ALDH1A1MAPT | |
| SCHEMBL559602 | 0.74 | PTGS2 (0.36) | ALDH1A1MAPT | |
| SCHEMBL18371551 | 0.73 | LMNA (0.33) | LMNAMAPK1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120012822-A1 | AROMATIC COMPOUND AND METHOD FOR PRODUCING SAME | KEIO UNIVERSITY (JP) | 2012-01-19 | — | — | US | disclosed |
| US-20120012822-A1 | AROMATIC COMPOUND AND METHOD FOR PRODUCING SAME | KEIO UNIVERSITY (JP) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120012822-A1 | AROMATIC COMPOUND AND METHOD FOR PRODUCING SAME | CCKBR, CCKAR, NPY2R | LMNA 1047/4885MAPK1 2063/4885ELANE 4849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.